NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Registering A CAGR Of 30.1% For The Forecast Period From 2018 To 2025 : Grand View Research Inc.
San Francisco, 9 July 2019: The Report NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs), And Segment Forecasts, 2018 – 2025 The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to reach USD 2.09 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidence of chronic liver diseases is expected to propel the demand for NASH biomarkers over the forecast period. The National Health and Nutrition Examination Survey recently found that approximately 30% of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone. This disease remains undiagnosed, as a liver can remain fatty without any change in its function. However, it can progress into a serious condition, known as nonalcoholic steatosis that may result in liver failure. NASH is characterized by...